Placebo‐controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy

OBJECTIVE: This double‐blind, randomized, placebo‐controlled Phase 2 study (NCT01462292) assessed the 24‐week efficacy, safety, tolerability, and pharmacokinetics of two different subcutaneous drisapersen doses, and the 24‐week off‐dose persistent effect, in ambulant Duchenne muscular dystrophy (DMD...

Descripción completa

Detalles Bibliográficos
Autores principales: McDonald, Craig M., Wong, Brenda, Flanigan, Kevin M., Wilson, Rosamund, de Kimpe, Sjef, Lourbakos, Afrodite, Lin, Zhengning, Campion, Giles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093847/
https://www.ncbi.nlm.nih.gov/pubmed/30128316
http://dx.doi.org/10.1002/acn3.579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093847/
https://www.ncbi.nlm.nih.gov/pubmed/30128316
http://dx.doi.org/10.1002/acn3.579

Ejemplares similares